United States Drug Manufacturers - General news

19:10 17 Jul 2026

Market source Regulatory and legal Main company 🇺🇸 United States

Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?

Novartis recently received traditional FDA approval for Fabhalta (iptacopan) to treat primary IgA nephropathy, converting its prior accelerated approval. This approval is based on strong clinical trial data showing Fabhalta slows kidney function decline, reinforcing Novartis's growing nephrology portfolio which also includes Vanrafia and …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

18:39 17 Jul 2026

Morningstar Earnings Main company 🇺🇸 United States

Novo Nordisk: EU Approval of Wegovy Pill Expands Opportunity, but Cash Pay Raises Systematic Risk

Novo Nordisk received EU approval for its Wegovy pill, expanding its market opportunity, particularly through cash-pay sales in Europe, the US, and UAE. Despite increasing the 2030 sales forecast for the Wegovy pill to $11 billion, Morningstar lowered Novo Nordisk's fair value estimate to …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

18:29 17 Jul 2026

Seeking Alpha Earnings Main company 🇺🇸 United States

Novo Nordisk: The Oral Wegovy Promise (NYSE:NVO)

Novo Nordisk has received EU approval for its oral Wegovy pill for weight management, marking the first GLP-1 receptor agonist in pill form cleared for this use in the region. This approval strengthens the company's obesity portfolio and offers patients an alternative to injectable …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

18:10 17 Jul 2026

The National Law Review Regulatory and legal Main company 🇺🇸 United States

AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against AstraZeneca PLC (AZN) after its late-stage Phase-3 CARDIO-TTransform trial for the amyloid cardiomyopathy treatment Wainua failed to meet its primary endpoint, causing a significant drop in the company's American Depositary Share (ADS) price. The …

AZN main company

Sharemaestro market context Price below Trend Line 52 weeks -1.4%

18:04 17 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal

Sector leader Eli Lilly is in a buy zone above a pivot at 1,133.95 ahead of second-quarter results, due on Aug. 5. Continue Reading

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

17:40 17 Jul 2026

Investor's Business Daily Deals and strategy Main company 🇺🇸 United States

Merck Reportedly Goes To Bat In Takeover Battle. But Genomics Stock Reverses.

Personalis (PSNL) stock initially surged before reversing lower following rumors that Merck (MRK) and at least two other companies, including Tempus AI (TEM), are attempting to acquire the genomics firm. Both Merck and Tempus AI currently hold stakes in Personalis. This development highlights potential …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

17:10 17 Jul 2026

Benzinga Regulatory and legal Main company 🇺🇸 United States

This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval

The FDA has granted full approval to Novartis's oral medication Fabhalta (iptacopan) to slow kidney function decline in adult patients with primary immunoglobulin A nephropathy (IgAN). This treatment could delay the need for dialysis or transplant for at-risk individuals. The decision was based on …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

17:10 17 Jul 2026

Seeking Alpha Regulatory and legal Main company 🇺🇸 United States

Novartis wins full FDA approval for kidney disease drug Fabhalta in IgA nephropathy

Novartis has received full FDA approval for its kidney disease drug Fabhalta (iptacopan), specifically for primary immunoglobulin A nephropathy, also known as Berger disease. Fabhalta is an oral Factor B inhibitor designed to treat this autoimmune condition. This approval marks a significant step for …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

17:10 17 Jul 2026

Intellectia AI Earnings Main company 🇺🇸 United States

Novartis Receives Full FDA Approval for Kidney Disease Therapy

Novartis has received full FDA approval for its kidney disease therapy, Fabhalta (iptacopan), for treating primary immunoglobulin A nephropathy (IgAN). Clinical trials showed significant improvement in estimated glomerular filtration rate over two years, solidifying its efficacy in slowing kidney function decline. This approval, coupled …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

17:00 17 Jul 2026

Medical Marketing and Media Market update Main company 🇺🇸 United States

With Up To Date campaign, Gilead brings HIV prevention into the dating conversation

Gilead Sciences has launched its "Up To Date" campaign, featuring comedians Nicole Byer and Devon Walker, to normalize conversations around HIV prevention, testing, and PrEP, particularly targeting Black women. The campaign uses humor and culturally relevant media placements like streaming services, social media, and …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

16:48 17 Jul 2026

finance.yahoo.com Analyst action Main company 🇺🇸 United States

Eli Lilly Long-Term GLP-1 Franchise Faces Limited Generic Threat, UBS Says

Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GL PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

16:31 17 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout

Eli Lilly LLY announced that it has entered into a definitive agreement to acquire New York-based clinical-stage biotech AtaiBeckley ATAI for an initial upfront payment of $2.8 billion. Shares of ATAI were up 33.4% yesterday following the announcement of the news. Lilly's interest in …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

16:07 17 Jul 2026

TradingView Market update Main company 🇺🇸 United States

ETFs Investing in Amgen Inc. Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Amgen Inc. (AMG) stocks, sorted by market value. It details various ETFs from issuers like Vanguard, BlackRock, Invesco, and State Street Corp., offering data such as their market value, weight of …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

15:39 17 Jul 2026

BioSpace Deals and strategy Main company 🇺🇸 United States

Aqemia and Sanofi Expand Their Research Collaboration

Aqemia and Sanofi have expanded their multi-year research collaboration, initially announced in December 2023. The expansion involves the nomination of a new therapeutic target and an additional milestone payment to Aqemia, bringing the potential total payments to $140 million. This partnership leverages Aqemia's generative …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

15:37 17 Jul 2026

The National Law Review Regulatory and legal Main company 🇺🇸 United States

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Biogen Inc. (BIIB) purchasers. This investigation follows a 6.4% stock price drop after Biogen announced that its Phase 2 CELIA study for diranersen failed to meet its primary endpoints on May 14, …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

14:40 17 Jul 2026

citybiz Deals and strategy Main company 🇺🇸 United States

Merck Reportedly Among Bidders as Personalis Explores Potential Sale

Personalis, a precision oncology company, is reportedly exploring a potential sale after attracting takeover interest from Merck & Co. and two other prospective buyers. The company has retained legal and financial advisors to assess strategic alternatives. Merck, which holds over a 10% stake in …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

14:38 17 Jul 2026

StocksToTrade Earnings Main company 🇺🇸 United States

MRK Stock Climbs As New Drugs And Targets Fuel Bull Case

Merck & Company Inc. (MRK) stock has risen by 2.77% due to positive drug trial results for LIPFENDRA and expanded approvals for KEYTRUDA. The company is also developing a promising HIV pipeline. Analysts have raised price targets for MRK, citing its strong drug pipeline …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

14:38 17 Jul 2026

Entrepreneur Deals and strategy Main company 🇺🇸 United States

Prozac Maker Eli Lilly Just Bought a Psychedelics Company for $2.8 Billion — Here’s What It Could Mean for Mental Health

Eli Lilly has acquired AtaiBeckley for $2.8 billion upfront, with potential for an additional $1 billion, as part of its aggressive expansion strategy. This acquisition gives Eli Lilly access to a DMT-based nasal spray currently in Phase 3 trials for treatment-resistant depression, which is …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

13:40 17 Jul 2026

Seeking Alpha Deals and strategy Main company 🇺🇸 United States

Personalis draws takeover interest from Merck (PSNL:NASDAQ)

Personalis (PSNL) shares surged in premarket trading after reports indicated the company is exploring a potential sale. Merck (MRK) and two other bidders have reportedly expressed takeover interest in the cancer test maker. This news suggests a significant acquisition opportunity in the biotech sector.

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

13:38 17 Jul 2026

The Business Journals Market update Main company 🇺🇸 United States

Eli Lilly files initial plans for $6.5B Generation Park manufacturing site

Eli Lilly has submitted initial plans for its massive $6.5 billion GLP-1 manufacturing plant in Houston's Generation Park. This move follows the pharmaceutical giant's significant announcement last year regarding its commitment to establishing a major pharmaceutical manufacturing site in Texas. The filings provide a …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

13:10 17 Jul 2026

Stock Titan Market update Main company 🇺🇸 United States

FDA clears Sarclisa Escena on-body injector for Sanofi (NASDAQ: SNY)

The US FDA has approved Sanofi's subcutaneous Sarclisa Escena (isatuximab-irfc) for multiple myeloma, making it the first anticancer treatment to be administered via an on-body injector or manual subcutaneous injection. This approval expands Sarclisa's use across all existing IV indications. The pivotal IRAKLIA phase …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

13:05 17 Jul 2026

Ad Hoc News Earnings Main company 🇺🇸 United States

Merck stock edges higher as Keytruda drives double digit growth

Merck's stock continues to show strong performance, driven primarily by the robust demand for its oncology drug Keytruda and HPV vaccine Gardasil. The company reported double-digit top-line growth and increased earnings per share in Q1 2025, with Keytruda sales reaching an estimated $7.3 billion …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

11:41 17 Jul 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Is Bristol-Myers Squibb (BMY) Reasonable After Its 32% Run?

Bristol-Myers Squibb (BMY) has seen a 31.9% return in the past year, leading to a mixed valuation picture. While the stock screens as undervalued on some market-based checks, with a fair P/E ratio of 19.2x compared to its current 17.0x, concerns about patent expirations …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

11:40 17 Jul 2026

Stock Titan Market update Main company 🇺🇸 United States

GSK (NYSE: GSK) halts camlipixant cough drug after Phase III data

GSK has decided to halt further development of camlipixant for refractory chronic cough (RCC) after mixed results from its CALM-1 and CALM-2 Phase III trials. While the 50mg dose achieved the primary endpoint of reducing cough frequency in CALM-1, it failed to meet statistical …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

11:25 17 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

SteelPeak Wealth LLC Acquires 20,118 Shares of Amgen Inc. $AMGN

SteelPeak Wealth LLC significantly increased its stake in Amgen Inc. by purchasing an additional 20,118 shares, bringing its total holdings to 135,846 shares valued at $47.8 million. Several other institutional investors also adjusted their positions in Amgen, indicating active investment interest. The article also …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

10:11 17 Jul 2026

Ad Hoc News Balance sheet Main company 🇺🇸 United States

Grifols stock trades around recent lows as leverage and governance remain under scrutiny

Grifols stock is currently trading near multi-year lows due to persistent investor concerns regarding its high leverage and corporate governance issues. Despite recent quarterly revenue growth and efforts to improve efficiency, the company's significant debt load of over EUR 9 billion and past reporting …

GRFS main company

Sharemaestro market context Price below Trend Line 52 weeks -23.4%

08:38 17 Jul 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Pfizer (PFE) Could Be 16% Undervalued On New FDA Approval In Bladder Cancer

Pfizer (PFE) recently received FDA approval for PADCEV plus Keytruda for muscle-invasive bladder cancer, which could suggest a 16% undervaluation based on a fair value of $29.19 per share. Despite past share price pressure, the new oncology approval and strong late-stage pipeline in oncology …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

08:31 17 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Assetmark Inc. Purchases 15,719 Shares of Amgen Inc. $AMGN

Assetmark Inc. increased its stake in Amgen Inc. by 6.9% in the first quarter, purchasing an additional 15,719 shares to bring its total holdings to 243,853 shares valued at approximately $85.8 million. Amgen's stock currently holds an overall "Hold" consensus among analysts, with an …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

08:11 17 Jul 2026

Novartis Deals and strategy Main company 🇺🇸 United States

Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next

Novartis is celebrating its 30th anniversary, reflecting on a 250-year legacy of scientific discovery rooted in the merger of Ciba-Geigy and Sandoz. The company has pioneered significant medical advancements, including targeted cancer therapies, cell therapy, and gene therapy, continually pushing the boundaries of what …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

02:38 17 Jul 2026

TradingView Market update Main company 🇺🇸 United States

ETFs Investing in Pfizer Inc. Stocks

This article lists numerous Exchange Traded Funds (ETFs) that hold Pfizer Inc. (PFE) stocks. It provides a detailed table including each ETF's market value, weight of PFE in the fund, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and 3-year NAV …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

01:11 17 Jul 2026

더밀크 Market update Main company 🇺🇸 United States

Sanofi Doesn’t Want AI to Automate Work. It Wants to Reinvent It.

Sanofi is aiming to become the first biopharma company powered by AI at scale, applying AI throughout the entire medicine development journey from discovery to commercialization. Emmanuel Frenehard, Sanofi's Chief Digital Officer, emphasizes that AI should be used to reinvent business processes rather than …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

00:38 17 Jul 2026

매일경제 Deals and strategy Main company 🇺🇸 United States

U.S. pharmaceutical company Eli Lilly announced on the 16th that it has decided to acquire mental he..

Eli Lilly announced its decision to acquire Ataybekli, a mental health treatment developer, for up to $3.8 billion. Ataybekli specializes in psychedelic drug-based treatments for depression and counts billionaire investor Peter Thiel among its early investors. The final acquisition is contingent on the performance …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

00:10 17 Jul 2026

GlobeNewswire Regulatory and legal Main company 🇺🇸 United States

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

Novartis announced that the FDA has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of disease progression. This approval, following an earlier accelerated approval, is based on data showing Fabhalta significantly slowed …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

23:52 16 Jul 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Is Gilead Sciences (GILD) Fully Valued Following Mixed Earnings And A Full Year EPS Miss?

Gilead Sciences (GILD) reported mixed Q2 earnings with revenue up 4.4% to $6.96 billion but missed full-year EPS estimates. While one valuation narrative suggests Gilead is 6.2% overvalued at $136.30 with a fair value of $128.38, another Discounted Cash Flow (DCF) model indicates it …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

23:11 16 Jul 2026

BioSpace Deals and strategy Main company 🇺🇸 United States

Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Organon (NYSE: OGN) announced it will release its second-quarter 2026 financial results through its Form 10-Q filing with the SEC, along with a Form 8-K disclosing non-GAAP financial measures. Due to its pending acquisition by Sun Pharmaceutical Industries Limited, the company has suspended quarterly …

OGN main company

Sharemaestro market context Trend signal active 52 weeks +46.5%

23:07 16 Jul 2026

Stock Titan Market update Main company 🇺🇸 United States

Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of common stock on July 15, 2026, for approximately $390,000, under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Dickinson still directly holds 168,646 shares. The sale was executed at an average …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%